Axitinib for renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 741-748

  Sonpavde, Guru ^a   Hutson, Thomas E ^a,b   Rini, Brian I ^c  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Axitinib; Multitargeted tyrosine kinase inhbitor; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; AUTOLOGOUS HEAT SHOCK PROTEIN PEPTIDE COMPLEX VACCINE; AXITINIB; BEVACIZUMAB; CANCER VACCINE; CD135 ANTIGEN; CYTOKINE; DOCETAXEL; EVEROLIMUS; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY G250; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; ADJUVANT THERAPY; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; FATIGUE; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIMB PAIN; MONOTHERAPY; MYALGIA; NAIL DISEASE; NAUSEA; NEPHRECTOMY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THYROID CANCER; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; DISEASE FREE SURVIVAL; DRUG SCREENING; KIDNEY TUMOR; MORTALITY; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG EVALUATION; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS;

EID: 44449152184     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.741     Document Type: Article

References (42)

1. Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med 2005;353:2477-90
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
3. Hilger RA, Scheullen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-8
4. Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001;98:7783-8
5. Alavi A, Hood JD, Frausto R, et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301:94-6
6. Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001;98:7783-8
7. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. mol Cell Biol 2002;22:7004-14
8. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2:S169-77
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
10. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
11. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2066;24(1):16-24
12. Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU1 1248) in bevacizumab-refractory metastatic renal cell carcinoma [abstract 4522]. Proc Am Soc Clin Oncol 2006;24:222s
13. Escudier B, Eisen T, Stadler WM, et al. Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Sorafenib, an Oral Multi-Kinase Inhibitor in Advanced Renal Cell Carcinoma. N Engl J Med 2007;356(2):125-34
14. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5023
15. Szczylik C, Demkow, T. Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5025
16. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
18. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2 based therapy. Proc Am Soc Clin Oncol 2003;22:851
19. Atkins M, McDermott D, Regan M, et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 2004;22(14S Suppl):4512
20. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179(1):81-6
21. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5038
22. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5106
23. Wood CG, Escudier B, Lacombe L, et al. A multicenter, randomized, phase 3 trial of a novel autologous therapeutic vaccine (Vitespen) versus observation as adjuvant therapy in patients at high risk of recurrence after nephrecromy for renal cell carcinoma [abstract 633]. Proc AUA Annual Meeting; 2007; Anaheim, CA, USA
24. Hurson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007;25(18S Suppl):5031
25. Wickman G, Hallin M. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Clin Cancer Res 2003;44:A3780
26. Axitinib Investigators Brochure, December 2002, Pfizer, Inc.
27. Mancuso MR, Davis I. Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21
28. Wilmes LJ, Pallavicini MG, Fleming LM, et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25(3):319-27
29. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
30. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23(24):5464-73
31. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
32. Rixe O, Meric, J, Bloch J, et al. Surrogate markets of activity of AG-013736, a muld-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 2005;23(16S):3003
33. Rini BI, Wilding GT, Hudes GR, et al. Axitinib in patients with metastatic renal cell cancer refractory to sorafenib. J Clin Oncol 2007;25 (18S):5032
34. Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18S Suppl):1003
35. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):7507
36. Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):6008
37. Spano J, Chodkiewicz C, Maurel J, et al. A randomized phase Il study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer preceded by a phase 1 component. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl);4551
38. Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a populatiou pharmacokinetic/ pharmacodynamic (PKPD) approach. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5027
39. Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 2007;12(19-20):806-12
40. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
41. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
42. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21